Trial Profile
An Explorative, Open-labeled, Phase I Study to Evaluate the Feasibility and the Safety of IMP321 in Combination With Immunotherapeutic/Targeted/Chemotherapeutic Agents or Via New Routes of Application in Advanced Stage Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Eftilagimod alpha (Primary) ; Eftilagimod alpha (Primary) ; Eftilagimod alpha (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Cervical cancer; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Lung cancer; Malignant-mesothelioma; Oesophageal cancer; Peritoneal cancer; Rectal cancer; Renal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms INSIGHT; INSIGHT Stratum D; INSIGHT-004; INSIGHT-005
- 04 Jan 2024 According to an Immutep Limited media release, company announced that the first patient has been enrolled and safely dosed in this trial.
- 03 Aug 2023 Number of treatment arms changed to 5, Planned number of patients changed from 45 to 110.
- 03 Aug 2023 Planned End Date changed from 30 Jun 2024 to 30 Sep 2025.